Interview with Michael Crow, Vice President & Area Director, GSK Pharma CIS
GSK CEO Andrew Witty has said that GSK must move away from selling “white pills in Western markets” in…
GSK Pharma CIS
Last updated: 01.06.2015
Address: 121614, Москва, Ул. Крылатская, дом 17, корп.3, эт.5, Бизнес-Парк “Крылатские Холмы” ,Russia
Tel: + 7 (495) 777 89 00
Web: http://www.glaxosmithkline.ru/home.aspx
Company description
We have a challenging and inspiring mission: to improve the quality of human life by enabling people to do more, feel better and live longer. This mission gives us the purpose to develop innovative medicines and products that help millions of people around the world.
We are one of the world’s leading research-based pharmaceutical and healthcare companies. Headquartered in the UK, we are a global organisation with offices in over 100 countries and major research centres in the UK, USA, Belgium and China.
But being a leader brings responsibility. This means that we care about the impact that we have on the people and places touched by our mission to improve health around the world.
It also means that we must help developing countries where debilitating disease affects millions of people and access to life-changing medicines and vaccines is a problem. To meet this challenge, we are committed to providing discounted medicines where they are needed the most.
Products and services
We are one of the few pharmaceutical companies researching both medicines and vaccines for the World Health Organization’s three priority diseases – HIV/AIDS, tuberculosis and malaria, and are very proud to have developed some of the leading global medicines in these fields.
We produce medicines that treat major disease areas such as asthma, anti-virals, infections, mental health, diabetes, cardiovascular and digestive conditions. In addition, we are a leader in the important area of vaccines and are developing new treatments for cancer.
Interviews
Related
Russia / Biocad Ramps up Sputnik V Manufacturing; Unlicensed Remdesivir Generics; Chinese Vaccine Rejection
The latest news from Russian pharma, including Biocad’s ramping up of Sputnik V COVID-19 vaccine manufacturing,…
Russia / $7.4 bln for Healthcare Modernisation; Generics Push; Sputnik Vaccine Successes
The latest news from Russian pharma and healthcare including a big funding injection for primary care up to 2025,…
COVID-19 / Russia First Mover in Approving Vaccine Amid Widespread Criticism
Russia has announced that a domestically developed COVID-19 vaccine has been approved by its health authorities,…
News Roundup / Russian Pharma: April 2020
Below is a selection of top stories in Russian pharma from recent months, ranging from proposed changes in…
Drug Shortages / An Increasing Concern in Russia
Russia is facing a drug shortage crisis which is having a particular impact on patients with life-threatening…
Russian bots targeted US and vaccines
In the latest twist in the ongoing story of Russian interference in the US presidential elections of 2016, it has…
Interview with Arman Voskertchyan, Managing Director, Johnson & Johnson…
In the United States, Johnson & Johnson has an image of being very close to people. Americans grow up with this…
Interview with Eric Blondeau, Managing Director, Alliance Healthcare Russia
You took over this organization just three months ago, having previously headed businesses in industries as diverse…
Interview with Victor Dmitriev, General Director, Association of the Russian…
The ARPM was founded in 2002, and you were its director from 2002-2004, before leaving for a post at the…
Interview with Vladimir Shipkov, Executive Director, Association of…
When Focus Reports prepared a report on the French pharmaceutical industry in 2009/10, we found that the head of…
Interview with Andrew Somers, President & CEO, American Chamber of Commerce…
The U.S. and Russia have a long history of trade, and you have personally been with the American Chamber of…
Interview with Svetlana Zavidova, Executive Director, Association of Clinical…
The primary objectives of this association are to promote Russia as a clinical trial destination, optimize the…
